Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331.
Leonard A MattanoMeenakshi DevidasKelly W MaloneyCindy WangAlison M FriedmannPatrick BuckleyMichael J BorowitzAndrew J CarrollJulie M Gastier-FosterNyla A HeeremaNina S Kadan-LottickYousif H MatloubDavid T MarshallLinda C StorkMignon L LohElizabeth A RaetzBrent L WoodStephen P HungerWilliam L CarrollNaomi J WinickPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Standard COG therapy without intensified pegaspargase, which can easily be given as an outpatient with limited toxicity, cures nearly all children with B-ALL identified as low-risk by clinical, early response, and favorable cytogenetic criteria.